Adanma Ayanambakkam, MD, discusses phase 1 data on darlifarnib plus cabozantinib in RCC

Jul 28, 2026 · 0:03:04

Listen to Episode

✨ AI Summary

Phase 1 data on darlifarnib plus cabozantinib presented.
Evaluation in patients with advanced renal cell carcinoma.
Adanma Ayanambakkam, MD, MS, highlights FIT-001 trial results.

Guests on This Episode

AM

Adanma Ayanambakkam, MD

1 podcast appearance

More from Urology Times

The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD

Aug 21, 2026 · 0:08:32

Kari Tikkinen, MD, PhD, discusses POISE-3 findings on tranexamic acid in urologic surgery

Aug 21, 2026 · 0:04:55

Expert APProach: Advancing APP Leadership & Expertise in Urology, With Susanne Quallich, PhD, ANP-BC

Aug 20, 2026 · 0:28:10

Mary Dunn, MSN, NP-C, OCN, RN, on advances reshaping advanced prostate cancer care

Aug 20, 2026 · 0:02:47

View all episodes →